Novo Nordisk A/S Common Stock (NVO)

Can Novo Nordisk thrive under intense competitive pressures?

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

The worst might be in the rearview mirror.

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

The weight loss drug market is on track to reach almost $100 billion.

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

These stocks have been struggling over the past year, but their growth days are far from over.

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Lilly's weight loss drugs have been delivering blockbuster revenue.

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

And he may be right.

The drugmaker is getting on the AI train in ways that could move the needle down the road.